Evaluation of a lysostaphin-fusion protein as a dry-cow therapy for Staphylococcus aureus mastitis in dairy cattle

This study evaluated the efficacy of a recombinant lysostaphin fused to a protein transduction domain (rLYS-PTD) as a dry-cow therapy for the treatment of experimentally induced chronic, subclinical Staphylococcus aureus mastitis. Twenty-two Holstein dairy cows were experimentally infected with Stap...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of dairy science Vol. 99; no. 6; p. 4638
Main Authors:	Hoernig, K J, Donovan, D M, Pithua, P, Williams, 3rd, F, Middleton, J R
Format:	Journal Article
Language:	English
Published:	United States 01-06-2016
Subjects:	Animals Anti-Bacterial Agents - therapeutic use Anti-Infective Agents, Local - therapeutic use Cattle Female Lysostaphin - therapeutic use Mammary Glands, Animal - drug effects Mammary Glands, Animal - microbiology Mastitis, Bovine - drug therapy Mastitis, Bovine - microbiology Staphylococcal Infections - drug therapy Staphylococcal Infections - microbiology Staphylococcal Infections - veterinary Staphylococcus aureus - drug effects Staphylococcus aureus mastitis lysostaphin dry-cow therapy
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	This study evaluated the efficacy of a recombinant lysostaphin fused to a protein transduction domain (rLYS-PTD) as a dry-cow therapy for the treatment of experimentally induced chronic, subclinical Staphylococcus aureus mastitis. Twenty-two Holstein dairy cows were experimentally infected with Staph. aureus in a single pair of diagonal mammary quarters approximately 45d before dry off. Staphylococcus aureus-infected mammary quarters of cows were randomly assigned to 1 of 2 treatment groups at dry off: (1) 279mg of rLYS-PTD in 50mL of vehicle (n=11 cows; 22 quarters) or (2) 50mL of vehicle solution (n=11 cows; 22 quarters) by intramammary infusion. All cows were followed for 30d postpartum to determine cure rates using bacteriologic culture, somatic cell counts, and clinical mastitis scores. No cures were recorded in either the treatment or control groups. Milk somatic cell count, bacterial colony counts, and mastitis scores did not significantly differ between treatment groups. In conclusion, rLYS-PTD was not an effective dry-cow therapeutic for chronic, subclinical Staph. aureus mastitis at the tested dose and formulation.
ISSN:	1525-3198
DOI:	10.3168/jds.2015-10783